Table 2 The Committee’s and the sample ranking of technologies evaluated by the 2006/7 Basket Committee (monthly cost threshold = 125 NIS)
Technology | Committee’s inclusion decision | Rank Basket Committee | Rank survey - Total | Rank survey - Physicians | Rank survey - Members of any Basket Committee | Rank efficiencya |
|---|---|---|---|---|---|---|
Crestor Ezetrol | YES | 1 | 18 | 18 | 15 | 12 |
Atacand Ocsaar Diovan Olmetec | YES | 2 | 29 | 29 | 25 | 3 |
Lantus Levemir | YES | 3 | 29 | 29 | 25 | 5 |
Apidra Humalog Novorapid | YES | 4 | 29 | 29 | 25 | 9 |
Eloxatin | YES | 5 | 15 | 15 | 15 | 4 |
Xeloda | YES | 6 | 15 | 15 | 15 | 1 |
Herceptin | YES | 7 | 11 | 11 | 12 | 23 |
Hepsera | YES | 8 | 3 | 3 | 3 | 16 |
Viread | YES | 9 | 9 | 8 | 7 | 22 |
Prevnar | YES | 10 | 33 | 33 | 33 | 32 |
Mabthera | YES | 11 | 1 | 1 | 1 | 14 |
Keppra | YES | 12 | 21 | 21 | 24 | 28 |
Zyprexa | YES | 13 | 22 | 22 | 22 | 6 |
Exjade | YES | 14 | 5 | 4 | 4 | 19 |
Plavix (cardiac) | YES | 15 | 8 | 8 | 5 | 10 |
Growth hormon | YES | 16 | 14 | 14 | 11 | 13 |
Plavix (stroke) | YES | 17 | 1 | 1 | 1 | 8 |
Velcade | YES | 18 | 4 | 5 | 5 | 27 |
Zomera | NO | 26.5 | 11 | 11 | 12 | 29 |
Apo-Go | NO | 26.5 | 6 | 6 | 9 | 21 |
Azilect | NO | 26.5 | 6 | 6 | 9 | 17 |
Cetuximab (Erbitux®) | NO | 26.5 | 25 | 24 | 25 | 31 |
Doxil | NO | 26.5 | 15 | 15 | 15 | 11 |
Emend | NO | 26.5 | 25 | 24 | 25 | 33 |
Erlotinib (Tarceva®) | NO | 26.5 | 25 | 24 | 25 | 30 |
Faslodex | NO | 26.5 | 11 | 11 | 12 | 24 |
Forteo | NO | 26.5 | 28 | 28 | 25 | 34 |
Gardasil | NO | 26.5 | 9 | 8 | 7 | 20 |
Lucentis | NO | 26.5 | 18 | 18 | 15 | 18 |
Rimonabant (Acomplia®) | NO | 26.5 | 34 | 34 | 34 | 25 |
Sifrol | NO | 26.5 | 20 | 20 | 21 | 26 |
Spiriva | NO | 26.5 | 29 | 29 | 25 | 7 |
Zemplar | NO | 26.5 | 22 | 22 | 22 | 15 |
Zyban | NO | 26.5 | 24 | 27 | 20 | 2 |
Mean rank | YES | 9.5 | 14.8 | 16.9 | 16.1 | 14.0 |
NO | 26.5 | 19.3 | 19.2 | 18.8 | 21.4 |